Grant: Alliance Grants
Université de Montréal
$61,731.00
Optimization of oxytetracycline dosing regimen and characterization of the effect of new alternative approaches in the treatment of colibacillosis in laying hens in Canada
FY 2023-24
Summary
The inappropriate use of antimicrobials in farm animals has been reported as a crucial factor in the spread of antimicrobial resistant (AMR). Oxytetracycline (OTC) is the only antimicrobial approved for the treatment of colibacillosis (caused by avian pathogenic Escherichia coli (APEC)) in laying hens in Canada. Despite the long-time availability of OTC on the market, microbiological data attesting its therapeutic efficacy in laying hens are lacking, although these data are crucial in OTC dosage optimization and in the prevention of AMR emergence, as raised by veterinary practitioners in this sector. Commonly, OTC is used in laying hens at the dose of 110 mg of OTC/kg of feed over a period varying between 7 and 14 days for the treatment of colibacillosis, without any scientific justification proving the relevance of this dosage regimen for the treatment of this disease. Moreover, there are no studies on the optimization of OTC regimens in the laying hen sector worldwide, while very few studies have evaluated the antibacterial activity of alternatives to antimicrobials in this animal production. Hence, this partnership aims to implement, for the first time, an effective veterinary antimicrobial stewardship (AMS) in the Canadian laying hen sector by optimizing the OTC dosage regimen, while characterizing the antibacterial activity of two innovative alternatives for both the treatment of colibacillosis and the reduction of OTC use in this sector. This project will enable the Fédération des Producteurs d'oeufs du Québec (FPOQ) to significantly reduce the economic losses associated with the non-marketing of eggs during the treatment with OTC, while preserving the efficacy of this highly valuable antibiotic. This project will also allow our two other industrial partners, Larvatria and Phytosynthese, to validate the efficacy of insect larva meal and phyto-derivatives (mixture of essential oils), respectively, in reducing both the incidence of colibacillosis and the use of OTC in the treatment of this disease in laying hens in Canada.The results of this partnership will be used at the national level by the various stakeholders in the Canadian laying hen industry to develop guidelines for responsible on-farm use of OTC.
Program
Alliance Grants
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
581109-2022
Name nom
Rhouma, Mohamed M
Department département
Pathologie et microbiologie
Organization id
63
Institution établissement
Université de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2023
Competition year année de concours
2022
Award amount
61731
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
102
Area of application group en
Agriculture and primary food production
Area of application group fr
Agriculture et produits alimentaires primaires
Area of application en
Animal management (animal diseases, breeding)
Area of application fr
Gestion des animaux (maladies animales, reproduction)
Research subject code
5201
Research subject group en
Microbiology
Research subject group fr
Bacteriology
Research subject en
Microbiologie
Research subject fr
Bactériologie
Application title
Optimization of oxytetracycline dosing regimen and characterization of the effect of new alternative approaches in the treatment of colibacillosis in laying hens in Canada
Keyword
Alternatives to antibiotics; Antimicrobial resistance; Antimicrobials-derived metabolites; Antimicrobial stewardship; Dosing regimen; E. coli; Food safety; Laying hens; Microbiota; Oxytetracycline
Application summary
The inappropriate use of antimicrobials in farm animals has been reported as a crucial factor in the spread of antimicrobial resistant (AMR). Oxytetracycline (OTC) is the only antimicrobial approved for the treatment of colibacillosis (caused by avian pathogenic Escherichia coli (APEC)) in laying hens in Canada. Despite the long-time availability of OTC on the market, microbiological data attesting its therapeutic efficacy in laying hens are lacking, although these data are crucial in OTC dosage optimization and in the prevention of AMR emergence, as raised by veterinary practitioners in this sector. Commonly, OTC is used in laying hens at the dose of 110 mg of OTC/kg of feed over a period varying between 7 and 14 days for the treatment of colibacillosis, without any scientific justification proving the relevance of this dosage regimen for the treatment of this disease. Moreover, there are no studies on the optimization of OTC regimens in the laying hen sector worldwide, while very few studies have evaluated the antibacterial activity of alternatives to antimicrobials in this animal production. Hence, this partnership aims to implement, for the first time, an effective veterinary antimicrobial stewardship (AMS) in the Canadian laying hen sector by optimizing the OTC dosage regimen, while characterizing the antibacterial activity of two innovative alternatives for both the treatment of colibacillosis and the reduction of OTC use in this sector. This project will enable the Fédération des Producteurs d'oeufs du Québec (FPOQ) to significantly reduce the economic losses associated with the non-marketing of eggs during the treatment with OTC, while preserving the efficacy of this highly valuable antibiotic. This project will also allow our two other industrial partners, Larvatria and Phytosynthese, to validate the efficacy of insect larva meal and phyto-derivatives (mixture of essential oils), respectively, in reducing both the incidence of colibacillosis and the use of OTC in the treatment of this disease in laying hens in Canada.The results of this partnership will be used at the national level by the various stakeholders in the Canadian laying hen industry to develop guidelines for responsible on-farm use of OTC.